Abivax shares rebounded after the company reported additional positive efficacy from the ABTECT Maintenance Part 2 supplemental portion of its Phase 3 ulcerative colitis (UC) program for obefazimod. In adults with moderately to severely active UC on continued 50 mg treatment, 37.2% of induction nonresponders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44. Abivax also reported that for patients whose doses were escalated to 50 mg, clinical remission was recaptured in 45.5% of those who relapsed during ABTECT Maintenance Part 1—an outcome the company said supports a practical dose-escalation strategy. The update arrived after earlier safety-related disclosures that triggered a sharp selloff. On safety, Abivax stated there were no new safety signals since a prior disclosure of malignancies in nine patients among 580 enrolled. The company’s exposure-adjusted incidence rates for malignancies excluding non-melanoma skin cancer (NMSC) and for NMSC were described as within pre-defined background reference ranges based on previous UC studies. The combination of efficacy reassurance and updated malignancy context was central to the renewed trading momentum, as investors weighed obefazimod’s benefit-risk profile for maintenance therapy.